Only $480—over $120 off retail price of $600
The "SmokerTest®" offers you:
* detection of lung cancer before the appearance of any clinical sign or radiological procedures;
* faster diagnosis in the presence of an isolated symptom;
* follow-up of the illness during treatment;
* post-treatment relapse watch, before any clinical signs.
All this through the expert utilization of a panel of four tumor-markers, with a blood sample. This panel includes the CEA, CA 125, NSE, Cyfra 21-1; TUMOR MARKERS are substances that can be detected in higher-than-normal amounts in the blood, of some patients with certain types of cancer. These substances are produced either by the tumor itself or by the body in response to the presence of cancer or certain benign (non-cancerous) conditions.These molecules (tumor markers) occurring in blood or tissue are associated with cancer; their measurement or identification is useful in patient diagnosis or clinical management. Our panel of 4 tumor-markers is of the greatest interest for an early diagnosis.
the first discovered tumor marker, the CEA is still largely used, in particular in lung cancer. Slight to moderate CEA elevations (rarely above 10 ng/ml) occur in 15-30% of benign diseases of the intestine, the pancreas, the liver and the lungs: liver cirrhosis, chronic hepatitis, pancreatitis, ulcerative colitis, Crohn's disease, emphysema. Smokers also have elevated CEA values.
The CA 125:
mainly used in the ovarian cancer, it’s also interesting in lung cancer when associated with other tumor markers. Slight to moderate elevations have been reported in individuals with non-malignant conditions such as cirrhosis, hepatitis, endometriosis, first trimester pregnancy, ovarian cysts, and pelvic inflammatory disease. Elevations during the menstrual cycle have also been mentioned. Non-ovarian malignancies include cervical, liver, pancreatic, lung, colon, stomach, biliary tract, uterine, fallopian tube, breast and endometrial carcinomas.
largely used in the small cells lung cancer, where marked increase is noticed ; its use with the Cyfra 21 in lung cancer treatment monitoring is of the utmost importance. NSE concentrations (inf 12 ng/ml) have been found in patients with benign pulmonary diseases and cerebral diseases. Moderate elevations are reported in cerebrovascular meningitis, disseminated encephalitis, spinocerebellar degeneration, cerebral ischemia and infarction, intracerebral hematoma, head injuries, inflammatory brain diseases, organic epilepsy, schizophrenia, and Jakob-Creutzfeld disease.
The Cyfra 21-1:
indifferent to histological type, CYF 21 is the panmarker for lung cancer because of its sensitivity which reaches 63% compared to 27% for CEA, 15% for SCC, 16% for NSE. Together with this sensitivity, CYF's exceptional specificity reaches 95%, and the readings are directly in proportion to the phase of the illness; the mean serological values increase progressively from contained to metastatic : CYFRA is the most stunning marker ever found. Not performed in the US, this marker is largely used in Europe and Japan for the epidermoidis forms of lung cancer.Slightly elevated values (up to 10 ng/ml) are rarely found in marked benign liver diseases and renal failure. The Cyfra21-1 is not available in the US, but largely used by top teams in Europe and Japan. For full benefit of patients.
Warning : a negative result NEVER means that you are not carrying an EARLY stage of cancer, but simply that there is no detectable cancer by biology at this time : it's good news for you nevertheless.
A distinctly positive result on one particular marker, or better on several, means that you will receive a commentary drawing your attention to the possibility of illness, and suggesting an immediate visit to your doctor (we will contact him if you so request).
A moderately high marker rate could suggest all kinds of benign conditions together with a more serious condition. A visit to your doctor would be essential in order to clarify the matter.
Record of results
It would be very useful to your doctor to have a record of your results should a cancer have been detected. In order to be able to judge the effectiveness of a specific treatment (your doctor may have to change it from time to time), it is important to have the starting values and the follow-up values of the appropriate marker(s) concerning the type of cancer being treated. We therefore recommend regular SmokerTest®. Analysis by CancerSafe® who will keep all your results in a medical file: YOUR medical file. Your file is protected by your own password and you can access it at any time. Once you have opened your file, you can E-mail or save your results in HTML format.
Values of tumor markers :
Normal range Moderate High values
CEA ng/ml <8 8-15 15-100,000
CA 125 U/ml <35 35-50 50-50,000
NSE ng/ml <21 21-40 40-4000
CYF21-1 ng/ml <3.5 3.5-5.0 5.0-1000
"Smokertest." Cancersafe. Cancersafe, Web. 9/2/11.